Nebilet (Nebivolol)

Nebivolol, the active ingredient in Nebilet, is a beta blocker presented as an oral tablet for oral use. It selectively blocks β1‑adrenergic receptors and promotes nitric‑oxide mediated vasodilation, helping to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets and providing reliable logistics for timely delivery.

Nebivolol is employed in the management of hypertension and related cardiovascular conditions.

Hypertension: reduces systolic and diastolic blood pressure, improving overall cardiovascular risk. Essential hypertension: provides sustained blood pressure control in primary hypertension. Isolated systolic hypertension: lowers elevated systolic pressure, especially in older adults.

Nebivolol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: general tiredness or reduced energy. - Nausea: upset stomach, sometimes with mild vomiting. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: significant drop in blood pressure causing faintness. - AV block: impaired electrical conduction between atria and ventricles. - Bronchospasm: constriction of airways, particularly in patients with asthma. - Allergic reactions: rash, itching, or swelling of face and throat. - Hepatic enzyme elevation: abnormal liver function tests.

Before initiating Nebivolol therapy, certain safety considerations should be observed.

Blood pressure monitoring: assess baseline values and follow‑up regularly. Heart rate assessment: watch for bradycardia, especially in patients with pre‑existing low rates. Renal impairment: evaluate kidney function and adjust dose if necessary. CYP2D6 inhibitors: avoid concomitant strong inhibitors that may increase nebivolol levels. Pregnancy and lactation: use only if potential benefit justifies the risk. Store at ambient temperature: keep in original container, protect from moisture and light.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): risk of severe AV block. - Abrupt clonidine withdrawal: may cause rebound hypertension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: enhanced hypotensive effect. - Diuretics: increased risk of orthostatic hypotension. - SSRIs or other antidepressants: possible changes in nebivolol metabolism.